PPARG and susceptibility to pneumonia measurement: Previous studies have shown that telmisartan, a novel angiotensin II type 1 receptor blocker, reduces mucin MUC5AC secretion in LPS-treated BEAS-2B cells (Chen et al., 2021) and alleviates LPS-induced pneumonia in rats by anti-inflammatory and anti-oxidative stress activity through peroxisome proliferator-activated receptor gamma (PPAR-γ)/NF-κΒ pathways (Zhou et al., 2022).